Galectin Therapeutics (FRA:PHPN) Ending Cash Position : €23.53 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Galectin Therapeutics Ending Cash Position?

Galectin Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was €23.53 Mil.

Galectin Therapeutics's quarterly Ending Cash Position increased from Jun. 2023 (€16.58 Mil) to Sep. 2023 (€19.08 Mil) and increased from Sep. 2023 (€19.08 Mil) to Dec. 2023 (€23.53 Mil).

Galectin Therapeutics's annual Ending Cash Position declined from Dec. 2021 (€35.09 Mil) to Dec. 2022 (€17.55 Mil) but then increased from Dec. 2022 (€17.55 Mil) to Dec. 2023 (€23.53 Mil).

Galectin Therapeutics Ending Cash Position Historical Data

The historical data trend for Galectin Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Ending Cash Position Chart

Galectin Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

42.73

22.31

35.09

17.55

23.53

Galectin Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															17.55	16.81	16.58	19.08	23.53

Galectin Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Galectin Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	17.049	+	6.481
	=	23.53

Galectin Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	18.672	+	4.858
	=	23.53

Galectin Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics (FRA:PHPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

GALT:USA

Address

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (FRA:PHPN) Headlines

No Headlines